Treating paediatric Crohn’s disease is challenging but new treatments hold promise
Author:
- 28 March 2024
- journal article
- review article
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 40 (3) , 121-126
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- The Future of Advanced Therapies for Pediatric Crohn’s DiseasePediatric Drugs, 2023
- Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension StudyClinical Gastroenterology and Hepatology, 2022
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialThe Lancet, 2022
- Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn’s Disease: ENTERPRISE StudyClinical Gastroenterology and Hepatology, 2022
- Pediatric Management of Crohn’s DiseaseGastroenterology Clinics of North America, 2022
- Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn’s DiseaseDigestive Diseases and Sciences, 2022
- Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2022
- Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI TrialClinical Gastroenterology and Hepatology, 2022
- Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study From the TROPIC ConsortiumClinical Gastroenterology and Hepatology, 2021
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialThe Lancet, 2017